1
|
Establishment of a tissue-engineered colon cancer model for comparative analysis of cancer cell lines. J Biomed Mater Res A 2024; 112:231-249. [PMID: 37927200 DOI: 10.1002/jbm.a.37611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2022] [Revised: 08/13/2023] [Accepted: 08/30/2023] [Indexed: 11/07/2023]
Abstract
To overcome the limitations of in vitro two-dimensional (2D) cancer models in mimicking the complexities of the native tumor milieu, three-dimensional (3D) engineered cancer models using biomimetic materials have been introduced to more closely recapitulate the key attributes of the tumor microenvironment. Specifically, for colorectal cancer (CRC), a few studies have developed 3D engineered tumor models to investigate cell-cell interactions or efficacy of anti-cancer drugs. However, recapitulation of CRC cell line phenotypic differences within a 3D engineered matrix has not been systematically investigated. Here, we developed an in vitro 3D engineered CRC (3D-eCRC) tissue model using the natural-synthetic hybrid biomaterial PEG-fibrinogen and three CRC cell lines, HCT 116, HT-29, and SW480. To better recapitulate native tumor conditions, our 3D-eCRC model supported higher cell density encapsulation (20 × 106 cells/mL) and enabled longer term maintenance (29 days) as compared to previously reported in vitro CRC models. The 3D-eCRCs formed using each cell line demonstrated line-dependent differences in cellular and tissue properties, including cellular growth and morphology, cell subpopulations, cell size, cell granularity, migration patterns, tissue growth, gene expression, and tissue stiffness. Importantly, these differences were found to be most prominent from Day 22 to Day 29, thereby indicating the importance of long-term culture of engineered CRC tissues for recapitulation and investigation of mechanistic differences and drug response. Our 3D-eCRC tissue model showed high potential for supporting future in vitro comparative studies of disease progression, metastatic mechanisms, and anti-cancer drug candidate response in a CRC cell line-dependent manner.
Collapse
|
2
|
Ratiometric Inclusion of Fibroblasts Promotes Both Castration-Resistant and Androgen-Dependent Tumorigenic Progression in Engineered Prostate Cancer Tissues. Adv Healthc Mater 2023; 12:e2301139. [PMID: 37450342 DOI: 10.1002/adhm.202301139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Revised: 06/30/2023] [Accepted: 07/12/2023] [Indexed: 07/18/2023]
Abstract
To investigate the ratiometric role of fibroblasts in prostate cancer (PCa) progression, this work establishes a matrix-inclusive, 3D engineered prostate cancer tissue (EPCaT) model that enables direct coculture of neuroendocrine-variant castration-resistant (CPRC-ne) or androgen-dependent (ADPC) PCa cells with tumor-supporting stromal cell types. Results show that the inclusion of fibroblasts within CRPC-ne and ADPC EPCaTs drives PCa aggression through significant matrix remodeling and increased proliferative cell populations. Interestingly, this is observed to a much greater degree in EPCaTs formed with a small number of fibroblasts relative to the number of PCa cells. Fibroblast coculture also results in ADPC behavior more similar to the aggressive CRPC-ne condition, suggesting fibroblasts play a role in elevating PCa disease state and may contribute to the ADPC to CRPC-ne switch. Bulk transcriptomic analyses additionally elucidate fibroblast-driven enrichment of hallmark gene sets associated with tumorigenic progression. Finally, the EPCaT model clinical relevancy is probed through a comparison to the Cancer Genome Atlas (TCGA) PCa patient cohort; notably, similar gene set enrichment is observed between EPCaT models and the patient primary tumor transcriptome. Taken together, study results demonstrate the potential of the EPCaT model to serve as a PCa-mimetic tool in future therapeutic development efforts.
Collapse
|
3
|
Abstract 4567: Transcriptomic analysis of a 3D engineered cancer model recapitulating stage-dependent heterogeneity in colorectal PDX tumors. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-4567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Colorectal cancer (CRC) is the third-most leading cause of cancer-related deaths in the United States. To advance the understanding of CRC tumor progression, models which mimic the tumor microenvironment (TME) and have translatable study outcomes are urgently needed. CRC patient-derived xenografts (PDXs) are promising tools for their ability to recapitulate tumor heterogeneity and key patient tumor characteristics, such as molecular characteristics. However, as in vivo models, CRC PDXs are costly and low-throughput, which leads to a need for equivalent in vitro models. To address this need, we previously established an in vitro model using a tissue engineering toolset with CRC PDX cells. However, it is unclear whether tissue engineering has the capacity to maintain patient- and/or cancer stage-specific tumor heterogeneity. To address this gap, we employed three PDX tumor lines, originated from stage II, III-B, and IV CRC tumors, in the formation of 3D engineered CRC PDX (3D-eCRC-PDX) tissues and performed an in-depth comparison between the 3D-eCRC-PDX tissues and the original CRC-PDX tumors. To form the tissues, CRC-PDX tumors were expanded in vivo and dissociated. The isolated cells were encapsulated within poly(ethylene glycol)-fibrinogen hydrogels and remained viable and proliferative post encapsulation over the course of 29 days in culture. To gain molecular insight into the maintenance of PDX line stage heterogeneity, we performed a transcriptomic analysis using RNA seq to determine the extent to which there were similarities and differences between the CRC-PDX tumors and the 3D-eCRC-PDX tissues. We observed the greatest correspondence in overlapping differentially expressed human genes, gene ontology, and Hallmark gene set enrichment between the 3D-eCRC-PDX tissues and CRC-PDX tumors in the stage II PDX line, while the least correspondence was observed in the stage IV PDX line. The Hallmark gene set enrichment from murine mapped RNA seq transcripts was PDX line-specific which suggested that the stromal component of the 3D-eCRC-PDX tissues was maintained in a PDX line-dependent manner. Consistent with our transcriptomic analysis, we observed that tumor cell subpopulations, including human proliferative (B2M+Ki67+) and CK20+ cells, remained constant for up to 15 days in culture even though the number of cells in the 3D-eCRC-PDX tissues from all three CRC stages increased over time. Yet, tumor cell subpopulation differences in the stage IV 3D-eCRC-PDX tissues were observed starting at 22 days in culture. Overall, our results demonstrate a strong correlation between our in vitro 3D-eCRC-PDX models and the originating in vivo CRC-PDX tumors, providing evidence that these engineered tissues may be capable of mimicking patient- and/or cancer stage-specific heterogeneity.
Citation Format: Yuan Tian, Iman Hassani, Benjamin Anbiah, Bulbul Ahmed, William Van Der Pol, Elliot J. Lefkowitz, Peyton C. Kuhlers, Nicole L. Habbit, Martin J. Heslin, Elizabeth A. Lipke, Michael W. Greene. Transcriptomic analysis of a 3D engineered cancer model recapitulating stage-dependent heterogeneity in colorectal PDX tumors. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4567.
Collapse
|
4
|
Tunable three-dimensional engineered prostate cancer tissues for in vitro recapitulation of heterogeneous in vivo prostate tumor stiffness. Acta Biomater 2022; 147:73-90. [PMID: 35551999 DOI: 10.1016/j.actbio.2022.05.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2021] [Revised: 04/21/2022] [Accepted: 05/05/2022] [Indexed: 11/24/2022]
Abstract
In this manuscript we report the establishment and characterization of a three-dimensional in vitro, coculture engineered prostate cancer tissue (EPCaT) disease model based upon and informed by our characterization of in vivo prostate cancer (PCa) xenograft tumor stiffness. In prostate cancer, tissue stiffness is known to impact changes in gene and protein expression, alter therapeutic response, and be positively correlated with an aggressive clinical presentation. To inform an appropriate stiffness range for our in vitro model, PC-3 prostate tumor xenografts were established. Tissue stiffness ranged from 95 to 6,750 Pa. Notably, xenograft cell seeding density significantly impacted tumor stiffness; a two-fold increase in the number of seeded cells not only widened the tissue stiffness range throughout the tumor but also resulted in significant spatial heterogeneity. To fabricate our in vitro EPCaT model, PC-3 castration-resistant prostate cancer cells were co-encapsulated with BJ-5ta fibroblasts within a poly(ethylene glycol)-fibrinogen matrix augmented with excess poly(ethylene glycol)-diacrylate to modulate the matrix mechanical properties. Encapsulated cells temporally remodeled their in vitro microenvironment and enrichment of gene sets associated with tumorigenic progression was observed in response to increased matrix stiffness. Through variation of matrix composition and culture duration, EPCaTs were tuned to mimic the wide range of biomechanical cues provided to PCa cells in vivo; collectively, a range of 50 to 10,000 Pa was achievable. Markedly, this also encompasses published clinical PCa stiffness data. Overall, this study serves to introduce our bioinspired, tunable EPCaT model and provide the foundation for future PCa progression and drug development studies. STATEMENT OF SIGNIFICANCE: The development of cancer models that mimic the native tumor microenvironment (TME) complexities is critical to not only develop effective drugs but also enhance our understanding of disease progression. Here we establish and characterize our 3D in vitro engineered prostate cancer tissue model with tunable matrix stiffness, that is inspired by this study's spatial characterization of in vivo prostate tumor xenograft stiffness. Notably, our model's mimicry of the TME is further augmented by the inclusion of matrix remodeling fibroblasts to introduce cancer-stromal cell-cell interactions. This study addresses a critical unmet need in the field by elucidating the prostate tumor xenograft stiffness range and establishing a foundation for recapitulating the biomechanics of site-of-origin and soft tissue metastatic prostate tumors in vitro.
Collapse
|
5
|
Abstract 175: Production of cancer tissue-engineered microspheres for high-throughput screening. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
There is a need for new in vitro systems that enable pharmaceutical companies to collect more physiologically-relevant information on drug response in a low-cost and high-throughput manner. For this purpose, three-dimensional (3D) spheroidal models have been established as more effective than two-dimensional models. Current commercial techniques, however, rely heavily on self-aggregation of dissociated cells and are unable to replicate key features of the native tumor microenvironment, particularly due to a lack of control over extracellular matrix components and heterogeneity in shape, size, and aggregate forming tendencies. In this study, we overcome these challenges by coupling tissue engineering toolsets with microfluidics technologies to create engineered cancer microspheres.
Specifically, we employ biosynthetic hydrogels composed of conjugated poly(ethylene glycol) (PEG) and fibrinogen protein (PEG-Fb) to create engineered breast and colorectal cancer tissue microspheres for 3D culture, tumorigenic characterization, and examination of potential for high-throughput screening (HTS). MCF7 and MDA-MB-231 cell lines were used to create breast cancer microspheres and the HT29 cell line and cells from a stage II patient-derived xenograft (PDX) were encapsulated to produce colorectal cancer (CRC) microspheres.
Using our previously developed microfluidic system, highly uniform cancer microspheres (intra-batch coefficient of variation (CV) ≤ 5%, inter-batch CV < 2%) with high cell densities (>20×106 cells/ml) were produced rapidly, which is critical for use in drug testing. Encapsulated cells maintained high viability and displayed cell type-specific differences in morphology, proliferation, metabolic activity, ultrastructure, and overall microsphere size distribution and bulk stiffness. For PDX CRC microspheres, the percentage of human (70%) and CRC (30%) cells was maintained over time and similar to the original PDX tumor, and the mechanical stiffness also exhibited a similar order of magnitude (103 Pa) to the original tumor.
The cancer microsphere system was shown to be compatible with an automated liquid handling system for administration of drug compounds; MDA-MB-231 microspheres were distributed in 384 well plates and treated with staurosporine (1 μM) and doxorubicin (10 μM). Expected responses were quantified using CellTiter-Glo® 3D, demonstrating initial applicability to HTS drug discovery. PDX CRC microspheres were treated with Fluorouracil (5FU) (10 to 500 μM) and displayed a decreasing trend in metabolic activity with increasing drug concentration. Providing a more physiologically relevant tumor microenvironment in a high-throughput and low-cost manner, the PF hydrogel-based cancer microspheres could potentially improve the translational success of drug candidates by providing more accurate in vitro prediction of in vivo drug efficacy.
Citation Format: Elizabeth A. Lipke, Wen J. Seeto, Yuan Tian, Mohammadjafar Hashemi, Iman Hassani, Benjamin Anbiah, Nicole L. Habbit, Michael W. Greene, Dmitriy Minond, Shantanu Pradhan. Production of cancer tissue-engineered microspheres for high-throughput screening [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 175.
Collapse
|
6
|
Abstract 3856: Elucidating the role of fibroblasts in CRPC and ADPC progression using 3D engineered prostate cancer tissues. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-3856] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Prostate cancer (PC) currently represents 7.5% of all new cancer cases; notably, the 5-year relative survival rate drops from 100% in localized cases to 30.2% in patients who present with metastases. There are no curative therapies for metastatic PC, and most men develop serial resistance to androgen suppression, resulting in a more aggressive disease state that is much more difficult to mitigate.
Fibroblasts have been implicated in cancer progression and are thought to intravasate alongside circulating tumor cells and prime metastatic sites for tumor growth. Our understanding of the precise mechanisms by which they contribute to PC, however, is relatively underdeveloped in comparison to other solid cancer types. Here, we report a three-dimensional (3D) engineered prostate cancer tissue (EPCaT) model comprised of PC-3 castration-resistant (CRPC) or LNCaP androgen-dependent (ADPC) PC cell lines in direct coculture with BJ-5ta fibroblasts. By specifically isolating this cell-cell interaction within a bioinspired poly(ethylene glycol)-fibrinogen (PF) matrix, our EPCaT model introduces the ability to monitor coculture-driven changes at a tissue, cellular, and transcriptomic level.
Temporal variations in EPCaT growth, cell and colony morphology, cell populations, and cell-mediated remodeling of the PF matrix were assessed. Changes in bulk transcriptomic expression were also quantified and differentially expressed genes (DEGs) were evaluated between CRPC and ADPC mono- and coculture conditions. Finally, to evaluate the clinical significance of our findings, EPCaTs were evaluated against normal and primary tumor tissue transcriptomic data acquired from the Cancer Genome Atlas (TCGA).
In comparison to monoculture EPCaTs, both CRPC- and ADPC-fibroblast coculture conditions resulted in an increase in the number of proliferative cells, morphological features of cancer cell migration, and cell-mediated remodeling of the PF matrix, all of which suggest a more aggressive cell phenotype. DEG and gene ontology analysis revealed coculture-driven changes in genes associated with important tumorigenic processes including ECM organization, angiogenesis, and epithelial cell proliferation and migration. Interestingly, fibroblast coculture had a significantly larger impact on the ADPC transcriptome in comparison to CRPC, suggesting that fibroblasts could play an elevated role in less aggressive disease states. Notable DEGs in ADPC coculture that were also clinically significant in the TCGA tumor versus normal comparison included an overexpression of OR51E2 which has been shown to increase epithelial cell proliferation and participate in the ADPC to CRPC switch, thus exacerbating PC progression. Future studies will augment the pathophysiological relevance of our EPCaT model by including patient-isolated cancer-associated fibroblasts from recurring and non-recurring patients.
Citation Format: Nicole L. Habbit, Benjamin Anbiah, Joshita Suresh, Yuan Tian, Luke S. Anderson, Megan L. Davies, Iman Hassani, Taraswi Mitra Ghosh, Balabhaskar Prabhakarpandian, Robert D. Arnold, Elizabeth A. Lipke. Elucidating the role of fibroblasts in CRPC and ADPC progression using 3D engineered prostate cancer tissues [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3856.
Collapse
|
7
|
Abstract 3753: Patient derived xenograft colorectal cancer in a micro-vascularized tumor on a microfluidic chip. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-3753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Colorectal cancer (CRC) is the third leading cause of cancer-related deaths in the United States. Cellular and biochemical cues from the tumor microenvironment (TME) modulate tumor aggressiveness including metastasis and treatment failure with cancer therapeutics. Conventional tumor models exhibit several shortcomings including lack of cell heterogeneity which limits their potential to examine more complex phenomena associated with drug testing applications. Patient-derived xenografts (PDX) represent an alternative model which maintains tumor heterogeneity. Physiological correlation of current preclinical models is limited by the degree of endothelial vascularization of tumor and incorporation of the tumor cell heterogeneity with an appropriate extracellular matrix to form a three-dimensional (3D) tumor. Herein, we have developed a micro-vascularized tumor on a chip model to examine the dynamics of tumor cell metastasis using CRC PDX lines.
PDX tumors established from stage II, III-B, IV adenocarcinomas were propagated subcutaneously in SCID-NOD mice. Two days prior to tumor dissociation, the tumor chip containing an intricate vascular network for the growth of endothelial cells was primed and coated with 200 µg/ml fibronectin. EA.hy926 endothelial cells were seeded in the vascular channel and were allowed to form a lumen over 48 hours. The excised PDX tumor was dissociated and the cells (20 x 106 cells/ml) were mixed with a polymer precursor containing Poly(ethylene glycol)-fibrinogen and the photoinitiator eosin Y, then seeded into the primary tumor chamber and crosslinked under visible light. Serum containing media was perfused through the vascular channel at a constant flow rate of 1µl/minute. Metastasis was observed by maintaining the chip long-term.
Significant differences (p = 0.034) in tumor cell migration in the chip (intravasation, tumor cell circulation through the vascular channel, invasion and extravasation) over time were observed between the PDX CRC stages. Stage II tumor cells intravasated to the vascular channel by day 8 followed by circulation and adhered to the endothelium as single circular cells or clusters by day 15. Stage III-B tumor cells were observed to intravasate, circulate, and adhere to the vascular channel by day 8, and the endothelium was overtaken by the cancer cells by day 8. Stage IV tumor cells began intravasation from the primary chamber to the vascular channel and circulated through the endothelium by day 8, while invasion to the secondary chamber adjacent to the primary chamber was observed by day 15. The Stage IV tumor cells also formed clusters in the vascular channel at a distant site and extravasated to the secondary chamber which is consistent with the staging of the tumor. Finally, this chip can be used for screening anti-cancer drugs for CRC patients.
Citation Format: Benjamin Anbiah, Iman Hassani, Bulbul Ahmed, Nicole Habbit, Michael Greene, Balabhaskar Prabhakarpandian, Elizabeth Lipke. Patient derived xenograft colorectal cancer in a micro-vascularized tumor on a microfluidic chip [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3753.
Collapse
|
8
|
Abstract 1915: In vivo prostate tumor tissue stiffness differs by tumor region and can be recapitulated in bioengineered prostate tumor tissues. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-1915] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Throughout the tumorigenic process, locational heterogeneities in tumor tissue microarchitecture develop as a result of aberrant angiogenesis and a subsequently induced oxygen and nutrient gradient within the three-dimensional (3D) mass. This phenomenon often results in differential tissue stiffness between the necrotic, quiescent, and proliferative tumor regions. In vitro, strong correlations have been found to exist between cell culture platform stiffness and acquired chemoresistance and varied drug response. Therefore, to accurately recapitulate the tumor microenvironment, biomimetic models must provide a mechanically similar scaffold. This study reports novel quantification of the in vivo prostate tumor stiffness and the ensuing development of tunable 3D bioengineered tumor tissue (BioTT) to successfully recapitulate in vivo mechanical cues in vitro.
In vivo samples were generated by subcutaneously injecting Matrigel-suspended metastatic prostate cancer cells (PC-3) into the flank of athymic NCr nude mice. Resultant tumors (300 – 1,500 mm3) were excised from the murine host and geometrically dissected to provide samples from the tumor core, midpoint, and periphery. The Young’s modulus was quantified via parallel plate compression under physiological conditions. The 3D BioTT model is comprised of poly(ethylene glycol)-fibrinogen (PF) with varying amounts of excess poly(ethylene glycol) diacrylate (PEGDA) to modulate the mechanical properties of the scaffold. PC-3 cancer cells and BJ-5ta human fibroblasts were encapsulated within the covalently crosslinkable biomaterial and co-cultured for 29 days in vitro. Cell viability was assessed by LIVE/DEAD staining and cellular morphology was visualized with Hoechst 33342, Phalloidin, and the anti-fibroblast immunomarker, TE-7. Temporal variations in cell populations were quantified by flow cytometry and mechanical stiffness characterization was again performed by parallel plate compression.
In vivo prostate cancer tumors presented a wide range of tissue stiffness heterogeneity (200 – 5,750 Pa), characterized by an increasing modulus with respect to locational progression from the core to the periphery (n = 48 per tumor region). The BioTT model successfully recapitulated the full tumor stiffness range through biomaterial composition modulation; the addition of excess PEGDA significantly stiffened the PF scaffold (p ≤ 0.05, n = 3). PC-3 and BJ-5ta cells survived the encapsulation process and remained viable throughout long-term co-culture. Visualization of the 3D cellular microenvironment revealed both cancer and stromal cells maintained characteristic morphology. In future studies, the BioTT will be extended to a microfluidic chip platform, thus augmenting the physiological relevancy of the model by incorporating dynamic shear conditions and the ability to monitor cancer cell metastasis.
Citation Format: Nicole L. Habbit, Benjamin Anbiah, Luke S. Anderson, Joshita Suresh, Iman Hassani, Matthew Eggert, Shanese L. Jasper, Balabhaskar Prabhakarpandian, Robert D. Arnold, Elizabeth A. Lipke. In vivo prostate tumor tissue stiffness differs by tumor region and can be recapitulated in bioengineered prostate tumor tissues [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1915.
Collapse
|
9
|
Abstract 999: In vivo breast tumor stiffness and vascular drug delivery recapitulated in a microfluidic tumor-on-a-chip. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-999] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Biomimetic tissue engineered microfluidic cancer models offer a higher degree of spatial, temporal and structural precision in controlling the physical parameters and component characteristics of the native tumor microenvironment (TME). Current models working to establish a biomimetic in vitro breast TME are limited by their ability to recapitulate various degrees of in vivo complexities and poor correlation of the diffusional gradients of oxygen, nutrients and anti-cancer drugs. To establish a model and address these challenges, we have used poly(ethylene glycol)-fibrinogen (PEG-Fb) as our biomimetic material to engineer 3D breast tumor tissues and recapitulate the mechanical stiffness of core, midpoint and peripherial zones of the native tumor in a vascularized microfluidic chip.
To assess the mechanical stiffness, the in vivo breast tumor (MDA-MB-231 flank xenograft in Athymic nude mice) and engineered tumor constructs were subjected to parallel plate compression test using Cell Scale Microsquisher and the resulting force versus displacement data was acquired to calculate Young’s modulus. Tumor mimetic (“high perfusion chip” (HPC) and “low perfusion chip” (LPC), differ with respect to the vascular network surrounding their respective primary and secondary tumor compartments were used in this study. Breast cancer-associated endothelial cells (hBTEC) were seeded in the vascular network and allowed to form a lumen. Metastatic breast cancer cells MDA-MB-231/ human foreskin fibroblast BJ5ta (ATCC) cells were mixed with polymer precursor solution containing PEG-Fb and Eosin Y. The precursor was loaded into the primary tumor compartment and cross-linked for 2 minutes under visible light. Stiffness was modulated by adding poly(ethylene glycol) diacrylate (PEGDA) to the polymer precursor for recapitulating the different zones of the in vivo tumor. hBTEC media was perfused through the endothelial cell networks were continuously monitored for cell behavior and metastasis.
In vivo breast tumor stiffness at core, midpoint and periphery was found to be within the range of the 3D engineered breast tumor tissues with time in culture through day 29. In the vascularized microfluidic chip, cell laden biomaterial was incorporated, the cancer cells were observed to undergo key events of the TME such as intravasation, circulating tumor cells in the endothelial vascular channel, adherence and migration to the secondary chamber resulting in metastasis. In the native TME there are regional differences in drug diffusion; TRITC dextran (4.4 kDa) was administered at a constant flow rate through the chips’ vascularized networks and found to have vascular network geometry and engineered tumor construct stiffness dependent differences in diffusion into the primary tumor chamber, mimicking the in vivo phenomena.
Citation Format: Benjamin Anbiah, Iman Hassani, Nicole Habbit, Lani Jasper, Deborah Ramsay, Balabhaskar Prabhakarpandian, Robert Arnold, Elizabeth Lipke. In vivo breast tumor stiffness and vascular drug delivery recapitulated in a microfluidic tumor-on-a-chip [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 999.
Collapse
|
10
|
Abstract 2844: In vitro recapitulation of in vivo obesity-promoted colorectal cancer growth using a patient-derived xenograft engineered tumor model. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-2844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Strong epidemiological evidence links obesity to an increased risk of colorectal cancer (CRC). However, the precise molecular mechanisms underlying such an association have not been fully elucidated, partly due to the lack of physiologically relevant models. Here, we established a novel PEG-fibrinogen-based engineered tumor model using patient-derived xenograft (PDX) CRC co-cultured with 3T3-L1 adipocytes and an orthotopically implanted PDX CRC model of obesity.
The PDX CRC cells were isolated from PDXs propagated subcutaneously in NOD-SCID mice and encapsulated within a biomimetic polymer, PEG-fibrinogen, to create 3D engineered PDX CRC tumors (3DePCCTs) or cultured in a standard 2D manner. We compared cell viability, colony area, and cell subpopulations within the 3DePCCTs and stiffness of the 3DePCCTs to the in vivo propagated tumors. A stage IV CRC tumor was employed in vivo and in vitro to study obesity-promoted tumor growth. Responsiveness of the 3DePCCTs to the growth promoting effects of obesity was investigated through continuous co-culture with insulin sensitive (IS) and resistant (IR) (treated with TNFα and 1% hypoxia) 3T3-L1 adipocytes (adipocytes replaced every 72 hrs). The responsiveness of the stage IV CRC PDX line was validated using an orthotopically implanted CRC model of obesity in which Rag1tm1Mom mice were fed a high fat Western diet + 4% sugar water (HFWD+S) to induce obesity or a chow diet to maintain a lean phenotype.
The cells within the 3DePCCTs remained viable and the PDX-line dependent differential growth of tumor colony area within the 3DePPCTs recapitulated line-dependent difference in in vivo tumor growth. Based on flow cytometry, human (70±3%) and Cytokeratin 20+ (31±1) cell subpopulations within the 3DePCCTs were similar to the original in vivo tumor tissue and maintained over time, whereas supporting mouse stromal cells took over 2D cultured cells (n=3 batches). Stiffness of the 3DePCCTs was within the range of the in vivo tumor tissue stiffness (0.3 to3.6 KPa, n=3 tissues). In vitro adipocytes maintained IR for at least 72 hrs based on significantly higher MCP1 (at least 10 folds) and lower GLUT4 (maximally 0.1 fold) (n=3 batches). The in vitro coculture model revealed a significantly (p < 0.05) greater number of cancer cell colonies within 3DePCCTs after 8 days of co-culture with IR adipocytes compared to IS adipocytes and this difference increased through day 29. In the in vivo model, a significant (p < 0.05) greater than 2-fold increase in weight of PDX CRC tumors grown in mice fed the HFWD+S diet was observed.
We have established the ability to maintain PDX CRC cells in 3D culture long-term (29 days) and generated a novel in vitro obesity-mimetic engineered tumor model that recapitulated the growth promoting effects of the in vivo orthotopic, IR tumor microenvironment and could be used to examine mechanistic questions and therapeutic targets.
Citation Format: Iman Hassani, Benjamin Anbiah, Bulbul Ahmed, Nicole L. Habbit, Michael W. Greene, Elizabeth A. Lipke. In vitro recapitulation of in vivo obesity-promoted colorectal cancer growth using a patient-derived xenograft engineered tumor model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2844.
Collapse
|